The launches of sipuleucel-T (Dendreon’s Provenge) and ipilimumab (Bristol-Myers Squibb’s Yervoy) in 2010 and 2011, respectively, represented the first notable immunotherapy approvals in anticancer treatment since the advent of the cytokines. Their approvals dramatically altered the treatment landscape in their respective indications—prostate cancer and malignant melanoma—and laid the foundations for the re-emergence of immunotherapy as a key treatment strategy in oncology. A plethora of cancer immunotherapies are in development for multiple oncology indications and present a highly lucrative opportunity for immunotherapy developers.
Markets covered: United States, France, Germany, Italy, Spain, United Kingdom, Japan.
Primary research: 23 interviews with thought leaders.
Epidemiology: Newly diagnosed incident cases and recurrent (or, for some indications, transformed)cases in select patient populations for malignant melanoma, non-small-cell lung cancer (NSCLC), renal cell carcinoma, glioblastoma multiforme, and prostate cancer, by country.
Population segments in market forecast: Malignant melanoma (resectable [stage II-III]; first-line unresectable/metastatic; second-line unresectable/metastatic; third-line unresectable/metastatic); NSCLC (newly diagnosed stage III; first-line advanced/metastatic; second-line advanced/metastatic; third-line advanced/metastatic); renal cell carcinoma (second-line metastatic; third-line metastatic; fourth-line metastatic); glioblastoma multiforme (first line; second line; third line); prostate cancer (first-line metastatic castrate-resistant).
Emerging therapies: Phase I/II: 50 drugs; Phase III/PR: 32 drugs; registered: 14 drugs.
Market forecast features: We forecast drug-treatable population sizes and drug sales for all patient segments annually through 2022.